RPID director acquires shares and new warrants
RAPID MICRO BIOSYSTEMS director Melinda Litherland increased her stake through a registered direct offering.
Rhea-AI Filing Summary
RAPID MICRO BIOSYSTEMS director Melinda Litherland increased her stake through a registered direct offering. She purchased 12,787 shares of Class A Common Stock at $1.955 per share and received accompanying Series A and Series B warrants to buy 12,787 shares each.
Following the transaction, she holds 100,687 Class A shares directly. The Series A warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B warrant has a $2.34 exercise price and expires on May 29, 2031. Both warrants become exercisable on November 29, 2026 and include a 4.99% beneficial ownership cap.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 38,361 shares
Grant/Award
3 txns
Insider
PEI MELINDA LITHERLAND
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series A Warrant (right to buy) | 12,787 | $0.00 | $0.00 |
| Grant/Award | Series B Warrant (right to buy) | 12,787 | $0.00 | $0.00 |
| Grant/Award | Class A Common Stock | 12,787 | $1.955 | $25K |
Holdings After Transaction:
Series A Warrant (right to buy) — 12,787 contracts (Direct);
Series B Warrant (right to buy) — 12,787 contracts (Direct);
Class A Common Stock — 100,687 shares (Direct)
Footnotes (2)
- F1. On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
- F2. The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Key Figures
Shares purchased: 12,787 shares
Purchase price: $1.955 per share
Shares after transaction: 100,687 shares
+5 more
8 metrics
Shares purchased
12,787 shares
Class A Common Stock bought in registered direct offering at $1.955
Purchase price
$1.955 per share
Price per share with accompanying Series A and B warrants
Shares after transaction
100,687 shares
Total Class A Common Stock directly held after acquisition
Series A warrant exercise price
$1.955 per share
Exercise price for 12,787 underlying Class A shares
Series B warrant exercise price
$2.34 per share
Exercise price for 12,787 underlying Class A shares
Beneficial ownership limit
4.99%
Cap on ownership after exercising Series A and B warrants
Series A warrant term
Expires May 29, 2027
Exercisable from November 29, 2026 until May 29, 2027
Series B warrant term
Expires May 29, 2031
Exercisable from November 29, 2026 until May 29, 2031
Key Terms
registered direct offering, Series A Warrant, Series B Warrant, Rule 16(b)-3, +1 more
5 terms
registered direct offering financial
"purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Series A Warrant financial
"an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock"
A Series A warrant is a contract issued alongside a company’s early funding round that gives the holder the right to buy a set number of shares later at a fixed price. Think of it like a coupon that lets an investor purchase stock at today’s agreed price even if the company’s value rises; it can boost potential upside for the warrant holder and create dilution for existing shareholders, so investors watch them when assessing ownership and future share value.
Series B Warrant financial
"an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock"
A Series B warrant is a tradable right issued alongside a Series B funding round that lets its holder buy a specified number of company shares at a fixed price for a set period. It matters to investors because exercising the warrant increases the total shares outstanding (dilution) and can be a cheap way to gain ownership if the company’s value rises — think of it like a coupon to buy stock later at today’s price.
Rule 16(b)-3 regulatory
"approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3"
beneficially own more than 4.99% financial
"would beneficially own more than 4.99% of the total number of shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Melinda Litherland acquire in the latest RPID Form 4 filing?
Melinda Litherland acquired 12,787 RPID common shares and related warrants. She purchased Class A Common Stock in a registered direct offering and received Series A and Series B warrants, each covering 12,787 underlying shares of Class A Common Stock as part of that transaction.
What prices and terms apply to the new RPID warrants reported for Melinda Litherland?
The Series A warrant has a $1.955 exercise price; Series B is $2.34. Both are exercisable starting November 29, 2026. The Series A warrant expires May 29, 2027, and the Series B warrant expires May 29, 2031, each for 12,787 underlying shares.
Is there a beneficial ownership limit on Melinda Litherland’s new RPID warrants?
Yes, the Series A and B warrants include a 4.99% ownership cap. They cannot be exercised if doing so would cause the holder, together with affiliates and related persons, to beneficially own more than 4.99% of RPID’s outstanding Class A Common Stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
